172 related articles for article (PubMed ID: 38272897)
21. Impact of 1q gains on treatment outcomes of patients with newly diagnosed multiple myeloma in a real-world Swedish population receiving modern treatment.
Lemonakis K; Olsson-Arvidsson L; Karlsson C; Johansson B; Hansson M
Eur J Haematol; 2023 Sep; 111(3):391-399. PubMed ID: 37271732
[TBL] [Abstract][Full Text] [Related]
22. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.
Pasvolsky O; Ghanem S; Milton DR; Rauf M; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Tang G; Aljawai Y; Khan HN; Kebriaei P; Lee HC; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Blood Cancer J; 2024 Jan; 14(1):4. PubMed ID: 38199987
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
25. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.
Wang Y; Xu J; Xu B; Li P; Yang Y; Wang W; Xu T; Maihemaiti A; Lan T; Wang P; Ren L; Zhou C; Aihemaiti X; Liu P
Cancer; 2023 Apr; 129(7):1005-1016. PubMed ID: 36704927
[TBL] [Abstract][Full Text] [Related]
26. Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature.
Barbieri E; Martino EA; Rivolti E; Quaresima M; Vigna E; Neri A; Morabito F; Gentile M
Expert Opin Biol Ther; 2024 May; 24(5):365-381. PubMed ID: 38757726
[TBL] [Abstract][Full Text] [Related]
27. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
Chen H; Chen H; Zhou Y; Xu W; Yu J; Xu Y; Zhou F
Hematology; 2023 Dec; 28(1):2225342. PubMed ID: 37343159
[TBL] [Abstract][Full Text] [Related]
29. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
[TBL] [Abstract][Full Text] [Related]
30. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
31. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Bumma N; Dhakal B; Fraser R; Estrada-Merly N; Anderson K; Freytes CO; Hildebrandt GC; Holmberg L; Krem MM; Lee C; Lekakis L; Lazarus HM; Mian H; Murthy HS; Nathan S; Nishihori T; Parrondo R; Patel SS; Solh M; Strouse C; Vesole DH; Kumar S; Qazilbash MH; Shah N; D'Souza A; Sidana S
Cancer; 2023 Jul; 129(14):2179-2191. PubMed ID: 37021929
[TBL] [Abstract][Full Text] [Related]
32. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
Shah GL; Landau H; Londono D; Devlin SM; Kosuri S; Lesokhin AM; Lendvai N; Hassoun H; Chung DJ; Koehne G; Jhanwar SC; Landgren O; Levine R; Giralt SA
Leuk Lymphoma; 2017 Aug; 58(8):1823-1831. PubMed ID: 28078910
[TBL] [Abstract][Full Text] [Related]
33. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Sonneveld P; Avet-Loiseau H; Lonial S; Usmani S; Siegel D; Anderson KC; Chng WJ; Moreau P; Attal M; Kyle RA; Caers J; Hillengass J; San Miguel J; van de Donk NW; Einsele H; Bladé J; Durie BG; Goldschmidt H; Mateos MV; Palumbo A; Orlowski R
Blood; 2016 Jun; 127(24):2955-62. PubMed ID: 27002115
[TBL] [Abstract][Full Text] [Related]
34. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
[TBL] [Abstract][Full Text] [Related]
35. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
36. The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China.
Chen Q; Han X; Zheng G; Yang Y; Li Y; Zhang E; Yang L; Dong M; He D; He J; Cai Z
Front Oncol; 2022; 12():1084683. PubMed ID: 36605445
[TBL] [Abstract][Full Text] [Related]
37. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Avet-Loiseau H; Bahlis NJ; Chng WJ; Masszi T; Viterbo L; Pour L; Ganly P; Palumbo A; Cavo M; Langer C; Pluta A; Nagler A; Kumar S; Ben-Yehuda D; Rajkumar SV; San-Miguel J; Berg D; Lin J; van de Velde H; Esseltine DL; di Bacco A; Moreau P; Richardson PG
Blood; 2017 Dec; 130(24):2610-2618. PubMed ID: 29054911
[TBL] [Abstract][Full Text] [Related]
38. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
An G; Xu Y; Shi L; Shizhen Z; Deng S; Xie Z; Sui W; Zhan F; Qiu L
Haematologica; 2014 Feb; 99(2):353-9. PubMed ID: 24213147
[TBL] [Abstract][Full Text] [Related]
39. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Kaiser MF; Hall A; Walker K; Sherborne A; De Tute RM; Newnham N; Roberts S; Ingleson E; Bowles K; Garg M; Lokare A; Messiou C; Houlston RS; Jackson G; Cook G; Pratt G; Owen RG; Drayson MT; Brown SR; Jenner MW
J Clin Oncol; 2023 Aug; 41(23):3945-3955. PubMed ID: 37315268
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
